Research Article

The prognostic value of lncRNA SNHG4 and its potential mechanism in liver cancer

Yan Jiao1, Yanqing Li2, Baoxing Jia1, Qingmin Chen1, Guoqiang Pan3, Fang Hua4 and Yahui Liu1

1Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China; 2Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, P.R. China; 3Department of Gastrointestinal Surgery, The First Hospital of Jilin University, Changchun, Jilin, 130021, P.R. China; 4Cardiovascular Internal Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Correspondence: Yahui Liu (liuyh_2008@yeah.net) and Fang Hua (huafangjdy@yeah.net)

Background and object: Emerging evidence shows that non-coding RNA functions as new gene regulators and prognostic markers in several cancers, including liver cancer. Here, we focused on the small nucleolar RNA host gene 4 (SNHG4) in liver cancer prognosis based on The Cancer Genome Atlas (TCGA) data.

Methods: The expression data and clinical information were downloaded from TCGA. Chi-square tests evaluated the correlation between SNHG4 expression and clinical parameters. Differences in survival between high and low expression groups (optimal cutoff value determined by ROC) from Cox regression analysis were compared, and P-value was calculated by a log-rank test. Kaplan–Meier curves were compared with the log-rank test. GSEA and ceRNA network were conducted to explore the potential mechanism.

Results: Data mining of lncRNA expression data for 371 patients with primary tumor revealed overexpression of SNHG4 in liver cancer. High SNHG4 expression was correlated with histological type (P = 0.01), histologic grade (P = 0.001), stage (P = 0.01), T classification (P = 0.004) and survival status (P = 0.013). Patients with high SNHG4 expression had poor overall survival and relapse-free survival compared with those with low SNHG4 expression. Multivariate analysis identified SNHG4 as an independent prognostic factor of poor survival in liver cancer. GSEA revealed related signaling pathway and ceRNA network explored the further mechanism.

Conclusion: High SNHG4 expression is an independent predictor of poor prognosis in liver cancer.

Introduction

Liver cancer is one of the most digestive system malignancies in the world [1]. The 5-year survival rate has not improved in spite of recent advance in the treatment of liver cancer. The clinicians apply the histological classification and some biomarkers, such as Ki67, CD34, and AFP, to evaluate patients’ prognosis in the nowadays. However, there is also a challenge for clinicians make a judgment of liver cancer patients’ prognosis. Novel molecular classification for prognosis is urgent.

Non-coding RNA has attracted much attention recently. There have been too many researches about long non-coding RNA and microRNA in the field of oncology. Also, some molecular has been recognized as novel biomarkers for prognosis, including XIST [2], PVT1 [3], and MALT1 [4]. Small nucleolar RNA host gene 4 (SNHG4), a novel non-coding RNA, has first reported in the research of directly irradiated and bystander cells and was found to be up-regulated in irradiated TK6 cells but were repressed in bystander cells [5]. A recent study has revealed that lncRNA SNHG4 was associated with poor survival and recurrence in human osteosarcoma [6].

© 2020 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
| Characteristics                      | Number of patients (%) |
|-------------------------------------|------------------------|
| **Age**                             |                        |
| <55                                 | 117(31.62)             |
| ≥55                                 | 253(68.38)             |
| **Gender**                          |                        |
| FEMALE                             | 121(32.61)             |
| MALE                               | 250(67.39)             |
| **Histological type**               |                        |
| Fibrolamellar Carcinoma             | 3(0.81)                |
| Hepatocellular Carcinoma            | 361(97.3)              |
| Hepatocholangiocarcinoma            | 7(1.89)                |
| **Histologic grade**                |                        |
| G1                                  | 55(14.82)              |
| G2                                  | 177(47.71)             |
| G3                                  | 122(32.88)             |
| G4                                  | 12(3.23)               |
| NA                                  | 5(1.35)                |
| **Stage**                           |                        |
| I                                   | 171(46.09)             |
| II                                  | 86(23.18)              |
| III                                 | 85(22.91)              |
| IV                                  | 5(1.35)                |
| NA                                  | 24(6.47)               |
| **T classification**                |                        |
| T1                                  | 181(48.79)             |
| T2                                  | 94(25.34)              |
| T3                                  | 80(21.56)              |
| T4                                  | 13(3.5)                |
| TX                                  | 1(0.27)                |
| NA                                  | 2(0.54)                |
| **N classification**                |                        |
| N0                                  | 252(67.92)             |
| N1                                  | 4(1.08)                |
| NX                                  | 114(30.73)             |
| NA                                  | 1(0.27)                |
| **M classification**                |                        |
| M0                                  | 266(71.7)              |
| M1                                  | 4(1.08)                |
| MX                                  | 101(27.22)             |
| **Radiation therapy**               |                        |
| NO                                  | 338(91.11)             |
| YES                                 | 8(2.16)                |
| NA                                  | 25(6.74)               |
| **Residual tumor**                  |                        |
| R0                                  | 324(87.33)             |
| R1                                  | 17(4.58)               |
| R2                                  | 1(0.27)                |
| RX                                  | 22(6.03)               |
| NA                                  | 7(1.89)                |
| **Vital status**                    |                        |
| DECEASED                            | 130(35.04)             |
| LIVING                              | 241(64.96)             |
| **Relapse**                         |                        |
| NO                                  | 179(56.29)             |
| YES                                 | 139(43.71)             |
| SNHG4                               |                        |
| High                                | 75(20.22)              |
| Low                                 | 296(79.78)             |
Table 2 The correlation between SNHG4 expression and clinical parameters

| Clinical characteristics | Variable | No. of patients | SNHG4 expression | $\chi^2$ | $P$-value |
|-------------------------|----------|----------------|------------------|--------|-----------|
|                         |          |                | High %           | Low %  |           |
| Age                     | $<$55    | 117            | 31 (41.33)       | 86 (29.15) | 3.5593    | 0.059    |
|                         | $\geq$55 | 253            | 44 (58.67)       | 209 (70.85) |           |          |
| Gender                  | FEMALE   | 121            | 28 (37.33)       | 93 (31.42) | 0.7023    | 0.402    |
|                         | MALE     | 250            | 47 (62.67)       | 203 (68.58) |           |          |
| Histological type       | Fibrolamellar | 3   | 0 (0)           | 3 (1.01) | 12.2954   | 0.010    |
|                         | Hepatocellular | 361 | 70 (93.33)     | 291 (98.31) |           |          |
|                         | 7        | 5 (6.67)       | 2 (0.68)        |       |           |
| Histologic grade        | G1       | 55             | 4 (5.41)         | 51 (17.47) | 16.3387   | 0.001    |
|                         | G2       | 177            | 29 (39.19)       | 148 (50.68) |           |          |
|                         | G3       | 122            | 37 (50)          | 85 (29.11) |           |          |
|                         | G4       | 12             | 4 (5.41)         | 8 (2.74)  |           |          |
| Stage                   | I        | 171            | 23 (32.39)       | 148 (53.62) | 10.4078   | 0.010    |
|                         | II       | 86             | 23 (32.39)       | 63 (22.83) |           |          |
|                         | III      | 85             | 24 (33.8)        | 61 (22.1)  |           |          |
|                         | IV       | 5              | 1 (1.41)         | 4 (1.45)   |           |          |
| T classification        | T1       | 181            | 23 (30.67)       | 158 (53.74) | 13.4311   | 0.004    |
|                         | T2       | 94             | 26 (34.67)       | 68 (23.13) |           |          |
|                         | T3       | 80             | 23 (30.67)       | 57 (19.39) |           |          |
|                         | T4       | 13             | 3 (4)            | 10 (3.4)   |           |          |
|                         | TX       | 1              | 0 (0)            | 1 (0.34)   |           |          |
| N classification        | N0       | 252            | 54 (72)          | 198 (67.12) | 0.7889    | 0.546    |
|                         | N1       | 4              | 1 (1.33)         | 3 (1.02)   |           |          |
|                         | NX       | 114            | 20 (26.67)       | 94 (31.86) |           |          |
| M classification        | M0       | 266            | 57 (76)          | 209 (70.61) | 1.0165    | 0.497    |
|                         | M1       | 4              | 1 (1.33)         | 3 (1.01)   |           |          |
|                         | MX       | 101            | 17 (22.67)       | 84 (28.38) |           |          |
| Radiation therapy       | NO       | 338            | 69 (100)         | 269 (97.11) | 0.9617    | 0.327    |
|                         | YES      | 8              | 0 (0)            | 8 (2.89)   |           |          |
| Residual tumor          | R0       | 324            | 66 (89.19)       | 258 (88.97) | 0.4091    | 0.959    |
|                         | R1       | 17             | 3 (4.05)         | 14 (4.83)  |           |          |
|                         | R2       | 1              | 0 (0)            | 1 (0.34)   |           |          |
|                         | RX       | 22             | 5 (6.76)         | 17 (5.88)  |           |          |
| Survival status         | DECEASED | 130            | 36 (48)          | 94 (31.76) | 6.2408    | 0.013    |
|                         | LIVING   | 241            | 39 (52)          | 202 (68.24) |           |          |

Bold term represents $P < 0.05$.

However, the prognostic role and potential mechanism of SNHG4 in liver cancer remain unclear. In the present study, we explored the SNHG4 expression in liver cancer and compared the relationship between SNHG4 expression and clinical parameters. In the further, we analyzed the effect of SNHG4 on the overall survival and relapse-free survival and made subgroup analysis to explore it in depth. Besides, we studied the related signaling pathway through GSEA and conducted the SNHG4-related ceRNA network.

Materials and methods

Data mining of TCGA database

SNHG4 expression pattern and its prognostic significance were validated from liver cancer tissues paired with normal liver tissues from the TCGA database by RNAseq (IlluminaHiSeq). The optic value of SNHG4 determined by ROC was used as a cutoff for defining the high and low SNHG4 expression groups. HCCDB database (http://lifeome.net/database/hccdb/home.html) was used to validate the results.
Table 3 Univariate and multivariate cox analysis of overall survival

| Parameters       | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  | Hazard ratio | 95%CI (lower-upper) | P-value | Hazard ratio | 95%CI (lower-upper) | P-value |
| Age              | 1.02        | 0.7–1.48            | 0.926   |             |                     |         |
| Gender           | 0.82        | 0.57–1.16           | 0.263   |             |                     |         |
| Histological type| 0.98        | 0.27–3.63           | 0.982   |             |                     |         |
| Histologic grade | 1.05        | 0.85–1.31           | 0.651   |             |                     |         |
| Stage            | 1.38        | 1.15–1.65           | 0.001   | 0.86        | 0.68–1.07           | 0.175   |
| T classification  | 1.65        | 1.38–1.98           | 0.000   | 1.84        | 1.45–2.34           | 0.000   |
| N classification  | 0.71        | 0.5–1.03            | 0.071   |             |                     |         |
| M classification  | 0.70        | 0.48–1.02           | 0.061   |             |                     |         |
| Radiation therapy| 0.52        | 0.26–1.03           | 0.061   |             |                     |         |
| Residual tumor   | 1.42        | 1.12–1.79           | 0.004   | 1.44        | 1.13–1.85           | 0.003   |
| SNHG4            | 2.83        | 1.91–4.2            | 0.000   | 2.83        | 1.9–4.23            | 0.000   |

Table 4 Univariable and multivariable cox analysis of relapse-free survival

| Parameters       | Univariate analysis | Multivariate analysis |
|------------------|---------------------|-----------------------|
|                  | Hazard ratio | 95%CI (lower-upper) | P-value | Hazard ratio | 95%CI (lower-upper) | P-value |
| Age              | 0.89        | 0.63–1.27           | 0.521   |             |                     |         |
| Gender           | 0.98        | 0.69–1.4            | 0.919   |             |                     |         |
| Histological type| 2.03        | 0.66–6.29           | 0.218   |             |                     |         |
| Histologic grade | 0.98        | 0.8–1.21            | 0.873   |             |                     |         |
| Stage            | 1.66        | 1.38–1.99           | 0.000   | 1.11        | 0.86–1.44           | 0.416   |
| T classification  | 1.78        | 1.49–2.12           | 0.000   | 1.65        | 1.26–2.15           | 0.000   |
| N classification  | 0.98        | 0.68–1.42           | 0.926   |             |                     |         |
| M classification  | 1.19        | 0.8–1.78            | 0.394   |             |                     |         |
| Radiation therapy| 0.75        | 0.26–2.17           | 0.592   |             |                     |         |
| Residual tumor   | 1.27        | 1.01–1.61           | 0.042   | 1.37        | 1.08–1.74           | 0.010   |
| SNHG4            | 2.06        | 1.37–3.1            | 0.001   | 1.95        | 1.29–2.96           | 0.002   |

Statistical analysis

Statistical analysis was performed using R (version 3.5.1) [7] and R packages including ggplot2 [8], pROC [9], and survival [10]. Patients were divided into two groups (SNHG4 high expression and SNHG4 low expression) by the proper threshold in ROC. Chi-squared tests were applied to assess the association between SNGH4 expression and clinicopathological features. Kaplan–Meier curve compared the overall/relapse-free survival between high and low SNHG4 expression groups with the log-rank test. The independent prognostic value of SNHG4 expression on liver cancer was assessed by univariate and subsequent multivariate Cox regression analysis. Differences were considered significant when $P < 0.05$.

GSEA

GSEA is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states [11,12]. In the present study, GSEA was performed by using the GSEA software 3.0 from the Broad Institute. The gene expression data were RNAseq data from TCGA-LIHC. The gene set of “h.all.v6.2.symbols.gmt”, which summarizes and represents specific, well-defined biological states or processes, was downloaded from the Molecular Signatures Database (http://software.broadinstitute.org/gsea/msigdb/index.jsp). The normalized enrichment score (NES) was acquired by analyzing with permutations for 1000 times. Gene sets with normal $P$-value $< 0.05$ and false discovery rate (FDR) $< 0.25$ were considered to be significantly enriched.

Conduction of ceRNA network

Differentially expression microRNAs and encoding genes between high SNHG4 group and low SNHG4 group were analyzed using limma packages [13], and adjust $P$ value $< 0.05$ is presented as significant. The predicted
miRNA–mRNA interactions were obtained from starbase v2.0 (http://starbase.sysu.edu.cn/starbase2/index.php) by defeat options [14,15]. The ceRNA network was conducted by merging DEMs, DEGs, and miRNA–mRNA interactions.

Enrichment analysis
Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed using the R language Cluster profiler package [16]. The cluster Profiler is a Bioconductor software package that provides statistical analysis of functional clustering of gene sets.

Results

Patient characteristics
The demographic and clinicopathological characteristics gene expression data of 371 patients with liver cancer are analyzed and shown in Table 1.

SNHG4 expression and association with clinicopathological variables
SNHG4 expression was significantly higher in liver cancer tissues ($n = 371$; $P < 0.05$) compared with normal liver tissues ($n = 50$), which was validated by HCCDB database (Supplementary Figure S1). Furthermore, significant differences in SNHG4 expression were found based on histological grade and stage (Figure 1). The patients with liver cancer were divided into high and low SNHG4 expression groups. And their clinicopathological parameters and survival outcomes were described in Table 2. The results proved a correlation between high SNHG4 expression and
Figure 2. High SNHG4 expression is correlated with shorter overall survival (OS)

High SNHG4 expression is correlated with shorter OS in patients with liver cancer (A) and the group of G1/G2 (B), G3/G4 (C), stage I/II (D), stage III/IV (E), male (F), female (G), younger (H), and older (I).

Histological type ($P = 0.01$), histologic grade ($P = 0.001$), stage ($P = 0.01$), T classification ($P = 0.004$), and survival status ($P = 0.013$).

High SNHG4 expression as an independent prognostic factor for poor overall survival

High SNHG4 expression was associated with poor overall survival ($P < 0.0001$; Figure 2), which was validated by HCCDB database (Supplementary Figure S2). Subsequent subgroup analysis proved that high SNHG4 expression was associated with poor overall survival of patients in all subgroup except for female ($P = 0.073$; Figure 2). According to univariate analysis, stage, T classification, residual tumor, and SNHG4 expression were associated with poor overall survival.
Figure 3. High SNHG4 expression is correlated with shorter relapse-free survival (RFS)
High SNHG4 expression is correlated with shorter RFS in patients with liver cancer (A) and the group of G1/G2 (B), G3/G4 (C), stage I/II (D), stage III/IV (E), male (F), female (G), younger (H), and older (I).

survival (Table 3). Further multivariate analysis determined the independent prognostic value of high SNHG4 expression for poor overall survival of liver cancer (hazard ratio: 2.84, 95% confidence interval: 1.90–4.23, \( P < 0.001 \); Table 3).

High SNHG4 expression as an independent prognostic factor for poor relapse-free survival
High SNHG4 expression was associated with poor relapse-free survival (\( P < 0.001 \); Figure 3). Subsequent subgroup analysis proved that high SNHG4 expression was associated with poor relapse-free survival of patients in all subgroup except for female (\( P = 0.46 \); Figure 3) and younger (\( P = 0.068 \); Figure 3). According to univariate analysis, stage, T classification, residual tumor, and SNHG4 expression were associated with poor relapse-free survival (Table
Figure 4. Enrichment plots from GSEA
Adipogenesis (A), bile acid metabolism (B), fatty acid metabolism (C), oxidative phosphorylation (D), peroxisome (E), and xenobiotic metabolism (F) are differentially enriched in SNHG4-related liver cancer.

Table 5 Gene sets enriched in expression-related phenotype

| Gene set                          | NES  | NOM P-val | FDR q-val |
|-----------------------------------|------|-----------|-----------|
| HALLMARK_OXIDATIVE_PHOSPHORYLATION| 2.21 | 0.01      | 0.01      |
| HALLMARK_ADIPGENESIS              | 2.19 | 0.00      | 0.00      |
| HALLMARK_FATTY_ACID_METABOLISM    | 2.14 | 0.00      | 0.00      |
| HALLMARK_BILE_ACID_METABOLISM     | 2.02 | 0.00      | 0.01      |
| HALLMARK_XENOBOTIC_METABOLISM     | 1.97 | 0.00      | 0.01      |
| HALLMARK_PEROXISOME               | 1.93 | 0.00      | 0.01      |

NES: normalized enrichment score; NOM: nominal; FDR: false discovery rate. Gene sets with NOM P-val <0.05 and FDR q-val <0.25 are considered as significant.

4). Further multivariate analysis determined the independent prognostic value of high SNHG4 expression for poor relapse-free survival of liver cancer (hazard ratio: 1.95, 95% confidence interval: 1.29–2.94, P = 0.002; Table 4).

SNHG4-related signaling pathway and ceRNA network
To identify SNHG4-related signaling pathway activated in liver cancer, we conducted the GSEA between low and high SNHG4 expression data sets. Significant differences (FDR < 0.25, NOM P-value < 0.05) in the enrichment of MSigDB Collection (h.all.v6.2.symbols.gmt) and the details are shown in Figure 4 and Table 5. Oxidative phosphorylation, adipogenesis, fatty acid metabolism, bile acid metabolism, xenobiotic metabolism, and peroxisome are differentially enriched in SNHG4 expression-related phenotype.
Figure 5. SNHG4-related ceRNA network and related signaling pathway
(A) SNHG4-related ceRNA network was constructed, the red circle represents the lncRNA SNHG4, green rectangles represent the microRNAs, and the blue circle represents the mRNA. GO biological process (B), cellular component (C), molecular function (D), and KEGG (E) enrichment of mRNA in the ceRNA network.

In order to explore the further mechanism of SNHG4, we select 12 down-regulated differentially expression microRNAs (DEMs) and 1142 up-regulated expression encoding genes (DEGs) between low and high SNHG4 expression groups differentially. Next, we merged DEMs, DEGs and predicted miRNA–mRNA targets and conducted the SNHG4-related ceRNA network (Figure 5A). GO and KEGG enrichment analysis revealed the related functions and signaling pathways of mRNAs in the ceRNA network (Figure 5B–E). The correlation between the expression of SNHG4 and mRNAs in the ceRNA network was provided in the Supplementary Information.

Discussion
Liver cancer is associated with a high mortality rate worldwide. Despite the advance of therapies, the poor prognosis of liver cancer is still inextricability. Therefore, it is important to find reliable biomarkers for diagnosis and prognosis in liver cancer. In recent years, bioinformatics has attracted much attention because of its significance in screening markers. We also have been working on the exploration biomarkers for different types of cancer by bioinformatics [17–31].
In the present study, we found the higher SNHG4 expression in liver cancer, and the relationship between SNHG4 expression and histological type, histologic grade, stage, T classification, and survival status. In the further, we analyzed the effect of SNHG4 on the overall survival and relapse-free survival, and made subgroup analysis to explore it in depth. Besides, we studied the related signaling pathway through GSEA and conducted the SNHG4-related ceRNA network.

Small nuclear RNA host genes (SNHGs), encoded by some lncRNAs, are a class of small RNA molecules and play a role in chemical modifications of other RNAs including rRNAs, tRNAs, and snRNAs. Recently, many studies have found that the aberrant expression of snoRNAs might act as an oncogene in the progression of the tumor. For example, Chen found that SNHG8 overexpressed in non-small cell lung carcinoma (NSCLC) [32], and Dong found that SNHG8 is an oncogene in human hepatocellular carcinoma [33], Meng found SNHG6 promotes glioma tumorigenesis in glioma [34], and Zhu found SNHG4 overexpressed in hepatocellular carcinoma [35]. Consistent with these studies, we found higher SNHG4 expression in liver cancer and it may be a biomarker.

As for the prognostic value of SNHGs, limited studies have deeply explored it. SNHG1, SNHG3, SNHG20 have been separately proved to be a prognostic biomarker in neuroblastoma [36], ovarian cancer [37], and colorectal cancer [38]. Besides, only Zhu made a bioinformatic analysis of lncRNAs and found SNHG4 might be valuable prognostic markers in HCC [35]. In the present study, we also made the same conclusion that SNHG4 expression is an independent predictor of poor prognosis in liver cancer. But we further studied the prognostic value of SNHG4 in the subgroup and found its limitation in female and younger patients, which may contribute to the precision medicine.

Considering for a potential mechanism of SNHG4, related studies were rare. M. Ahmad Chaudhry first found SNHG4 might be involved in the bystander effect, a phenomenon that the irradiated cells communicate with unirradiated cells and induce changes in them [5]. Recently, Rudia Xu found that LncRNA SNHG4 promotes tumor growth by sponging miR-224-3p in osteosarcoma [6]. In the present study, we made the GSEA analysis and found that oxidative phosphorylation, adipogenesis, fatty acid metabolism, bile acid metabolism, xenobiotic metabolism, and peroxisome are differentially enriched in SNHG4 expression-related phenotype. Besides, we conducted the SNHG4-related ceRNA network and provided the clue for the future studies. There are still need to explore the underground mechanism by experiments in this field.

To our knowledge, this is the first study identifying a correlation between the expression level of SNHG4 and the prognosis of patients with liver cancer and exploring related mechanism. The results of our study have shown that the up-regulation of SNHG4 expression is associated with poor survival and has an independent prognostic role in liver cancer. Our study provides a new insight that SNHG4 played a valuable role in the prognosis of liver cancer, which may have an influence on the signaling pathway and laid a foundation for further studies to explore the SNHG4-related ceRNA mechanisms in deep.

Acknowledgement
The results shown here are partly based upon data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Author Contribution
Yan Jiao and Yanqing Li wrote the manuscript. Yanqing Li, Baoxing Jia, Qingmin Chen, and Guoqiang Pan contributed to data collection and analysis. Yan Jiao and Yahui Liu had a significant role in the study design and manuscript review. Fang Hua revised the manuscript. All authors read and approved the final manuscript.

Ethics Approval
Ethics committee approval was not necessary because all clinical data used in this study were obtained from a public database and are available for research.

Abbreviations
NSCLC, non-small cell lung carcinoma; OS, overall survival; RFS, relapse-free survival; SNHG4, small nucleolar RNA host gene 4; TCGA, The Cancer Genome Atlas.
33 Dong, J. et al. (2018) lncRNA SNHG8 Promotes the Tumorigenesis and Metastasis by Sponging miR-149-5p and Predicts Tumor Recurrence in Hepatocellular Carcinoma. Cell. Physiol. Biochem. 51, 2262–2274, https://doi.org/10.1159/000495571

34 Meng, Q. et al. (2018) Long non-coding RNA SNHG6 promotes glioma tumorigenesis by sponging miR-101-3p. Int. J. Biol. Markers 33, 148–155, https://doi.org/10.1177/1724600817747524

35 Zhu, Q. et al. (2019) Bioinformatic analysis of the prognostic value of the lncRNAs encoding snoRNAs in hepatocellular carcinoma. Biofactors. 45, 244–252, https://doi.org/10.1002/biof.1478

36 Sahu, D. et al. (2016) Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Oncotarget 7, 58022–58037, https://doi.org/10.18632/oncotarget.11158

37 Hong, L. et al. (2018) Upregulation of SNHG3 expression associated with poor prognosis and enhances malignant progression of ovarian cancer. Cancer Biomark 22, 367–374, https://doi.org/10.3233/CBM-170710

38 Li, C. et al. (2016) Increased long noncoding RNA SNHG20 predicts poor prognosis in colorectal cancer. BMC Cancer 16, 655, https://doi.org/10.1186/s12885-016-2719-x